Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TOTAL REVENUE OF $70 MILLION IN THE THIRD QUARTER OF 2025 CONTINUED SUCCESSFUL EXECUTION OF SANOFI PARTNERSHIP WITH $225 MILLION IN MILESTONES ACHIEVED YEAR-TO-DATE INCLUDING $50 MILLION EARNED ON MARKETING AUTHORIZATION TRANSFERS SANOFI REPORTED PRELIMINARY POSITIVE IMMUNOGENICITY AND SAFETY PHASE 1/2 DATA FOR NUVAXOVID  IN COMBINATION WITH BOTH FLUZONE HIGH-DOSE AND FLUBLOK SANOFI RECEIVED BARDA GRANT FOR PANDEMIC INFLUENZA VACCINE CANDIDATE USING NOVAVAX'S MATRIX-M ADJUVANT MARYLAND SITE CONSOLIDATION TRANSACTIONS RESULTED IN $60 MILLION CASH PROCEEDS AND APPROXIMATELY $230 MILLION IN EXPECTED FUTURE COST SAVINGS RAISES FULL YEAR 2025 REVENUE FRAMEWORK AND AFFIRMS FINANCIAL GUIDANCE C OMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. ET GAITHERSBURG, MD.

NOVAVAX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

NOVAVAX HAS SUCCESSFULLY ACHIEVED U.S. BLA APPROVAL AND COMPLETED BOTH EU AND U.S. MARKETING AUTHORIZATION TRANSFERS FOR NUVAXOVID TO SANOFI IN LINE WITH ITS CLA AND ITS CORPORATE STRATEGY, SECURING A TOTAL OF $225 MILLION IN NON-DILUTIVE CAPITAL YEAR-TO-DATE 2025 GAITHERSBURG, MD. , NOV. 4, 2025 /PRNEWSWIRE/ --NOVAVAX, INC. (NASDAQ: NVAX) HAS COMPLETED THE TRANSFER OF THE U.S. MARKETING AUTHORIZATION FOR ITS COVID-19 VACCINE, NUVAXOVID TO SANOFI, ENABLING SANOFI TO TAKE FULL RESPONSIBILITY FOR COMMERCIAL AND REGULATORY ACTIVITIES IN THE U.S. AND FULFILLING PART OF ITS COLLABORATION AND LICENSE AGREEMENT (CLA).

NOVAVAX COMPLETES U.S. MARKETING AUTHORIZATION TRANSFER TO SANOFI FOR NUVAXOVID, TRIGGERING A $25 MILLION MILESTONE PAYMENT

GAITHERSBURG, MD. , OCT. 30, 2025 /PRNEWSWIRE/ --NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED IT WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS AT 8:30 A.M.

NOVAVAX TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 6, 2025

AGREEMENTS SIGNED TO TRANSFER ONE U.S.-BASED FACILITY AND SELL CERTAIN EQUIPMENT NETTING $60 MILLION IN CASH AND RESULTING IN FUTURE CASH SAVINGS OF $230 MILLION NOVAVAX HEADQUARTERS TO REMAIN IN GAITHERSBURG, MD. GAITHERSBURG, MD.

NOVAVAX EXECUTES PLANNED SITE CONSOLIDATION, FURTHER REDUCING COST FOOTPRINT IN LINE WITH CORPORATE STRATEGY

GAITHERSBURG, MD. , OCT. 7, 2025 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) HAS COMPLETED THE TRANSFER OF THE MARKETING AUTHORIZATION FOR ITS COVID-19 VACCINE, NUVAXOVID TO SANOFI, IN THE EUROPEAN UNION (EU) ENABLING SANOFI TO TAKE FULL RESPONSIBILITY FOR COMMERCIAL AND REGULATORY ACTIVITIES IN THE EU.

NOVAVAX CONTINUES TO DELIVER ON SANOFI PARTNERSHIP, COMPLETING NUVAXOVID EU MARKETING AUTHORIZATION TRANSFER AND TRIGGERING $25 MILLION MILESTONE PAYMENT

GAITHERSBURG, MD. , SEPT. 30, 2025 /PRNEWSWIRE/ --NOVAVAX, INC. (NASDAQ: NVAX)TODAY ANNOUNCED PROGRESS ON ITS COLLABORATION AND LICENSE AGREEMENT(CLA) WITH SANOFIREGARDING NOVAVAX'S MATRIX-MADJUVANT.

NOVAVAX ANNOUNCES PROGRESS ON SANOFI AGREEMENT

GAITHERSBURG, MD. , SEPT. 4, 2025 /PRNEWSWIRE/ --NOVAVAX, INC. (NASDAQ: NVAX)TODAY ANNOUNCED A MILESTONE PAYMENT* FROM TAKEDA HAS BEEN TRIGGERED BY REGULATORY APPROVAL FOR NOVAVAX'S COVID-19 VACCINE NUVAXOVID INTRAMUSCULAR INJECTION 1 ML FORMULATED TO TARGET SARS-COV-2 OMICRON LP.8.1 AS AN INITIAL IMMUNIZATION (FIRST AND SECOND VACCINATION) FOR THOSE AGED SIX YEARS OR OLDER AND A BOOSTER IMMUNIZATION (AFTER THE THIRD VACCINATION) FOR THOSE AGED 12 YEARS OR OLDER.

NUVAXOVID NOW APPROVED IN JAPAN TRIGGERING TAKEDA MILESTONE PAYMENT

NUVAXOVID IS THE ONLY PROTEIN-BASED, NON-MRNA COVID-19 VACCINE AVAILABLE IN THE U.S. FOR THE 2025-2026 VACCINATION SEASON GAITHERSBURG, MD. , AUG. 27, 2025 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX)TODAY ANNOUNCEDTHAT THE U.S. FOOD AND DRUG ADMINISTRATION HAS APPROVED THE NUVAXOVID 2025-2026 FORMULA FOR THE PREVENTION OF COVID-19 IN ADULTS 65 YEARS AND OLDER OR INDIVIDUALS 12 YEARS THROUGH 64 YEARS OF AGE WITH AT LEAST ONE UNDERLYING CONDITION THAT PUTS THEM AT HIGH RISK FOR SEVERE OUTCOMES FROM COVID-19.

NOVAVAX'S NUVAXOVID 2025-2026 FORMULA COVID-19 VACCINE APPROVED IN THE U.S.

REFINANCING EXTENDS MATURITY OF MOST EXISTING DEBT WITH IMPROVED TERMS $225 MILLION OF CONVERTIBLE NOTES DUE IN 2031 ISSUED, INCLUDING A ~$175 MILLION EXCHANGE FOR THE RETIREMENT OF EXISTING CONVERTIBLE NOTES DUE IN 2027 AND ~$50 MILLION OF NEW MONEY GAITHERSBURG, MD. , AUG. 21, 2025 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED THAT IT HAS ENTERED INTO PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN OF THE HOLDERS OF ITS EXISTING 5.00% CONVERTIBLE SENIOR NOTES DUE 2027 (THE "2027 NOTES") AND NEW INVESTORS, PURSUANT TO WHICH THE COMPANY WILL ISSUE $225 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 4.625% CONVERTIBLE SENIOR NOTES DUE 2031 (THE "2031 NOTES") CONSISTING OF (I) APPROXIMATELY $175.3 MILLION PRINCIPAL AMOUNT OF 2031 NOTES ISSUED IN EXCHANGE FOR APPROXIMATELY $148.7 MILLION PRINCIPAL AMOUNT OF 2027 NOTES (THE "EXCHANGE TRANSACTIONS"), AND (II) APPROXIMATELY $49.7 MILLION PRINCIPAL AMOUNT OF 2031 NOTES FOR CASH (THE "SUBSCRIPTION TRANSACTIONS" AND, TOGETHER WITH THE EXCHANGE TRANSACTIONS, THE "TRANSACTIONS").

NOVAVAX ANNOUNCES CONVERTIBLE DEBT REFINANCING

TOTAL REVENUE OF $239 MILLION IN THE SECOND QUARTER OF 2025 RECEIVED FDABLA APPROVAL FOR NUVAXOVID, THE ONLY RECOMBINANT PROTEIN-BASED, NON-MRNA COVID-19 VACCINE AVAILABLE IN THE U.S.; APPROVAL TRIGGERED $175 MILLION MILESTONE PAYMENT FROM SANOFI COMPLETED TRANSITION OFNUVAXOVID COMMERCIAL LEADERSHIP IN THE U.S. TO SANOFI FOR THE 2025-2026 COVID-19 VACCINATION SEASON COVID-19- INFLUENZA -COMBINATION AND STAND-ALONE INFLUENZA VACCINE CANDIDATES SHOWED ROBUST IMMUNE RESPONSES IN INITIAL COHORT OF A PHASE 3 TRIAL WITH NEW T-CELL RESPONSE DATA IN BOTH NOVAVAX VACCINE CANDIDATES NUMERICALLY HIGHER THAN IN THE COMPARATOR FLUZONE HD ARM UPDATED FULL YEAR 2025 REVENUE FRAMEWORK AND FINANCIAL GUIDANCE C OMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. ET GAITHERSBURG, MD.

NOVAVAX REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

GAITHERSBURG, MD. , JULY 30, 2025 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED IT WILL REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS AT 8:30 A.M.

NOVAVAX TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

PEER-REVIEWED DATA SHOWSNOVAVAX'S H5N1 VACCINE CANDIDATE DEMONSTRATED IMMUNOGENICITY AGAINST CURRENTLY CIRCULATING VARIANTS FOLLOWING EITHER SINGLE OR TWO-DOSE ADMINISTRATION POTENTIAL FOR SINGLE INTRANASAL OR INTRAMUSCULAR DOSE COULD DIFFERENTIATE NOVAVAX'S VACCINE AS PART OF PANDEMIC EMERGENCY PREPAREDNESS EFFORTS GAITHERSBURG, MD. , JULY 24, 2025 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED PRECLINICAL DATA DEMONSTRATING THAT NOVAVAX'S H5N1 AVIAN PANDEMIC INFLUENZA VACCINE CANDIDATE, LEVERAGING NOVAVAX'S RECOMBINANT, PROTEIN-BASED NANOPARTICLE TECHNOLOGY AND MATRIX-MADJUVANT, INDUCED ROBUST IMMUNE RESPONSES BY EITHER SINGLE OR TWO-DOSE INTRANASAL (IN) OR INTRAMUSCULAR (IM) ADMINISTRATION IN NONHUMAN PRIMATES.

Novavax, Inc.

NVAX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Novavax, Inc.

NVAX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVAX